Consistent with the hepatoprotective effects of LXRα being exerted directly in hepatocytes, treatment with an LXRα expressing virus normalized body weight (Extended Data Fig. 8a) and prevented liver injury and hepatic fibrosis (Fig. 5b,c,g,h) despite adverse effects on serum triglycerides (Fig. 5d) and restoration of hepatic steatosis (Fig. 5g). This evidence concerns the gene NR1H3 and Hepatic steatosis.